AKT1 and acute myeloid leukemia: In particular, mTor/AKT pathway is constitutively activated in 50-70% of AML cases, and mTor inhibitors, such as Rapamycin and Everolimus [35], have been proved effective, although highly toxic [32], in patients with relapsed/refractory AML.